Please assess the completion status of the following clinical trial:

Trial Title: Effect of Low-dose vs. High-dose Pitavastatin on In-stent Restenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of informed consent prior to any study specific procedures~2. Patients between the age of 30 to 79~3. Non-ST elevation Acute coronary syndrome with successful everolimus eluting stent implantation (with TIMI flow grade 3 after the procedure)~Exclusion Criteria:~1. Hypersensitivity to pitavastatin~2. Unable to perform OCT and NIRS~3. Serum creatinine \> 2.0 mg/dL.~4. Steroid or hormone replacement therapy~5. Hemoglobin A1c \>9%~6. Type 1 diabetes~7. Decreased serum platelet level (\< 100,000/uL)~8. Need for chronic oral anticoagulant therapy or chronic low-molecular-weight heparin~9. Life expectancy less than a year~10. Renal failure requiring dialysis or anticipated need for dialysis during the course of the study~11. Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study~12. Involvement in the planning and/or conduct of the study~13. Left ventricular ejection fraction \< 40%~14. Hepatic dysfunction (aspartate aminotransferase or alanine aminotransferase \> twice the upper limit)~15. Gastrointestinal disorder such as Crohn's disease~16. Alcohol abuse~17. Known pregnancy, breast-feeding, or intend to become pregnant during the study period

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Low dose 1mg pitavastatin (Type: ACTIVE_COMPARATOR): pitavastatin 1mg which is considered low dose statin will be administered for 36 months
- High dose 4mg pitavastatin (Type: ACTIVE_COMPARATOR): pitavastatin 4mg which is considered high dose statin will be administered for 36 months

Based on this trial design, predict the completion outcome and termination type (if applicable).